Peptide Reference
Bremelanotide
Bremelanotide (Vyleesi)
A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as needed before sexual activity.
Status
approved
Category
sexual
Typical cost
$900-1200/month
Mechanism
Activates melanocortin receptors in the CNS to increase sexual desire and arousal. Works through neural pathways rather than vascular mechanisms (unlike Viagra).
Potential benefits
- FDA-approved for HSDD
- Works within 45 minutes
- Non-hormonal
- As-needed dosing
- Increases sexual desire
Reported side effects
- Nausea (40%)
- Facial flushing
- Injection site reactions
- Headache
- Vomiting
Common dosing references
subcutaneous
1.75mg · As needed (45 min before)
PRN, max 8x/month
Research notes
Bremelanotide RECONNECT trials
2019
Significant improvements in sexual desire and distress in premenopausal women
Regulatory and sourcing notes
FDA-approved as Vyleesi for HSDD in premenopausal women. Prescription required.
Prescription only. Auto-injector pen. Can be compounded but brand name Vyleesi preferred.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides